↓ Skip to main content

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)

Mentioned by

twitter
7 tweeters

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Published in
Journal for Immunotherapy of Cancer, August 2018
DOI 10.1186/s40425-018-0393-z
Pubmed ID
Authors

Christine A. Garcia, Alex El-Ali, Tanya J. Rath, Lydia C. Contis, Vikram Gorantla, Jan Drappatz, Diwakar Davar

Abstract

PD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are uncommon occurrences with varied presentations. We describe two separate cases of ipilimumab associated meningoencephalomyelitis and demyelinating polyneuropathy with unusual presentations. Two melanoma patients were treated with ipilimumab in the adjuvant setting. The first patient developed a meningoencephalitis following 3 doses of ipilimumab. MRI imaging of the brain confirmed leptomeningeal enhancement although cerebrospinal fluid (CSF) analyses were negative for malignant cells consistent with meningoencephalomyelitis. Although she initially improved following treatment with steroids and intravenous immunoglobulin, she subsequently relapsed. She was successfully treated with infliximab and made a complete neurological recovery. A second patient developed progressive lower extremity weakness following two doses of ipilimumab. MRI imaging of the spine confirmed diffuse nerve root enhancement consistent with acute inflammatory demyelinating polyneuropathy (AIDP). He was treated with high dose steroids with resolution of neurological symptoms. Both patients remain disease free. Neurological irAEs are uncommon adverse events in the context of CTLA-4 and/or PD-1 inhibitor therapy. Care must be taken to distinguish these from leptomeningeal disease. Early recognition of neurological irAEs is critical for the initiation of specific anti-inflammatory agents to prevent and potentially reverse neurological sequelae.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 18%
Researcher 9 15%
Student > Doctoral Student 5 8%
Student > Postgraduate 4 6%
Student > Bachelor 4 6%
Other 11 18%
Unknown 18 29%
Readers by discipline Count As %
Medicine and Dentistry 20 32%
Neuroscience 7 11%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 3 5%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 6 10%
Unknown 21 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2019.
All research outputs
#4,317,106
of 15,289,603 outputs
Outputs from Journal for Immunotherapy of Cancer
#574
of 1,140 outputs
Outputs of similar age
#95,430
of 274,853 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 15,289,603 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them